|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. Cost
of Sales
Total cost of sales increased to $178.7 million for the
first half of 2009 from $143.4 million in the first half of
2008. Included within cost of sales were other charges of
$20.9 million (2008: $Nil), as described in Note 5 to
the interim financial statements. Excluding other charges, the
gross margin as a percentage of revenue was 59% for both the
first half of 2009 and 2008.
Included within total cost of sales is $74.3 million of
directly incurred collaboration cost of sales expenses related
to Tysabri for the first half of 2009 (2008:
$55.9 million), resulting in a reported Tysabri
gross margin of 61% in the first half of 2009 (2008: 58%).
The reported Tysabri gross margin is impacted by the
profit sharing and operational arrangements in place with Biogen
Idec.
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Cost
of Sales
Cost of sales increased 9% to $121.2 million from
$111.5 million in 2007. Included within cost of sales were
other charges of $Nil (2007: $0.2 million), as described
below. Excluding other charges, the gross margin on revenue was
59% in 2008, compared to 61% in 2007. The fluctuation in the
gross profit margin in 2008, as compared to 2007, was
principally a result of changes in product mix. In 2008, our
royalties were 47% of total manufacturing revenue and royalties
(2007: also 47%).
Table of Contents
Financial Review
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Cost
of Sales
Cost of sales was $123.7 million in 2008, compared to
$114.2 million in 2007 and $123.3 million in 2006. The
gross profit margin was 59% in 2008, 61% in 2007 and 56% in
2006. The fluctuation in the gross profit margin in 2008, as
compared to 2007 and 2006, was principally a result of changes
in product mix and reduced amortized fees. In 2008, our
royalties were 47% of total manufacturing revenue and royalties
(2007: also 47%; 2006: 44%).
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Cost
of Sales
Cost of sales decreased 14% to $111.5 million from
$130.4 million in 2006. Included within cost of sales were
other charges of $0.2 million (2006: $2.5 million), as
described below. Excluding other charges, the gross margin on
revenue was 61% in 2007, compared to 48% in 2006. The increase
in the gross profit margin in 2007 as compared to 2006 was
principally a result of changes in product mix. Royalties
continue to grow as a percentage of total manufacturing revenue
and royalties. In 2007, our royalties were 47% of total
manufacturing revenue and royalties (2006: 44%).
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Cost
of Sales
Cost of sales was $113.7 million in 2007, compared to
$122.9 million in 2006 and $112.1 million in 2005. The
cost of sales as a percentage of revenue was 38% for 2007, 44%
for 2006 and 43% for 2005, resulting in a gross profit margin of
62% in 2007, 56% in 2006 and 57% in 2005. The fluctuation in the
gross profit margin in 2007 as compared to 2006 and 2005 was
principally a result of changes in product mix. Royalties
continue to grow as a percentage of total manufacturing revenue
and royalties. In 2007, our royalties were 47% of total
manufacturing revenue and royalties (2006: 44%; 2005: 34%).
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Cost
of Sales
Total cost of sales was $198.9 million in 2006 and
$178.7 million in 2005, an increase of 11%. Cost of sales
as a percentage of product revenue was 41% for 2006, compared to
43% for 2005, and the gross margin on product revenue increased
from 57% in 2005 to 59% in 2006, principally as a result of
changes in the mix of product revenues.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Cost
of Sales
Cost of sales was $196.1 million in 2005, compared to
$173.6 million in 2004. The cost of sales as percentage of
product revenue was 43% for both 2005 and 2004. The gross margin
remained consistent with 2004 because of compensating changes in
the mix of product revenues, the impact of the Tysabri
voluntary suspension and the divestment of products in 2004.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Cost of Sales
Cost of sales increased by 26% to $178.7 million from
$142.0 million for 2004. Cost of sales as a percentage of
product revenue was 43% for 2005, compared to 48% for 2004. The
gross margin on product revenue increased from 52% in 2004 to
57% in 2005, principally as a result of changes in the mix of
product revenues.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Cost
of Sales
Cost of sales was $173.6 million in 2004, compare to
$248.9 million in 2003. The cost of sales as percentage of
product revenue was 43% for 2004 and 42% for 2003. The margin
remained consistent with 2003 despite the change in the mix of
product revenues. This was due primarily to the divestment of a
number of products and businesses with higher margins and was
offset by the elimination of royalties paid to Pharma Marketing
Ltd. (Pharma Marketing) in 2004 (2003: $43.3 million).
There were no direct costs of sales related to our royalty
revenue in 2004 and 2003.
This excerpt taken from the ELN 6-K filed Apr 11, 2005. (A) Cost of Sales Exceptional cost of sales include $3.4 million on the impairment of certain manufacturing fixed assets, severance/relocation costs of $4.1 million and other exceptional cost of sales of $(0.6) million. | EXCERPTS ON THIS PAGE:
|
| |||||||
